(:GNBT)

Jul 26, 2021 09:00 am ET
Generex Biotechnology Corporation Subsidiary, Olaregen Therapeutix Announces its Malaysian Distribution Partner, Nexgen Medical, has gained approval for the use of Excellagen® Wound Conforming Matrix
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix announced in May that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive...
Jun 22, 2021 10:17 am ET
NuGenerex Immuno-Oncology Secures $535 Million Valuation from World-Class Independent Valuation & Appraisal Firm
NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions...
May 11, 2021 09:00 am ET
Generex Biotechnology Subsidiary NuGenHealth Contracts with Westside Medicine & Cardiology, Inc. to Provide Remote Patient Monitoring (RPM) Services
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative...
May 10, 2021 09:00 am ET
Generex Posts Recording of May 6 Shareholder Conference Call Highlighting its Ii-Key COVID Complete Vaccine™ and its Go-Forward Plans for Revenue Producing Assets
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative...
May 06, 2021 08:30 am ET
Generex Biotechnology Subsidiary NuGenHealth Contracts with Florida Health Care Associates to Provide Remote Patient Monitoring (RPM) Services
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative...
May 05, 2021 12:20 pm ET
Generex Provides Clarification on Its Ii-Key COVID-19 Complete Vaccine China Partnership Agreement
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative...
May 04, 2021 01:12 pm ET
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Thursday May 6, 2021 at 9:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative...
May 03, 2021 09:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Agreement with Nexgen Medical for Distribution of Excellagen® Wound Conforming Matrix in Malaysia
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) subsidiary Olaregen Therapeutix today announced that the company has executed a Distribution Agreement with Nexgen Medical Sdn Bhd, Inc. (“Nexgen”) to be Generex’s exclusive...
Apr 27, 2021 08:30 am ET
Generex Provides Update on its Ii-Key COVID-19 Complete Vaccine Program: Advancing Global Development
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that in connection with its partnership with the National Institute for Viral Disease Control and Prevention, Chinese...
Apr 12, 2021 08:00 am ET
NuGenerex Immuno-Oncology Submits Protocol, Data, and Manufacturing Information to FDA in Advance of the IND Submission
NuGenerex Immuno-Oncology (NGIO – www.nugenerexio.com), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (“Generex” or the “Company”), an innovative and integrated healthcare holding company with end-to-end...
Apr 08, 2021 09:00 am ET
Last Chance for Children is Proud to Announce its Partnership with Generex Biotechnology & NuGenerex Immuno-Oncology to SAFELY and EFFECTIVELY Vaccinate Children and Pregnant Women
Last Chance for Children’s (LCFC) Mission is to help save children’s lives anywhere in the world. Due to the COVID-19 pandemic we are now focusing our efforts to help eradicate this virus so we could safely and effectively vaccinate children in...
Mar 31, 2021 11:03 am ET
Generex Biotechnology Announces Shareholder Conference Call Scheduled for Thursday May 6, 2021
Generex Biotechnology Corporation (OTCQB: GNBT) (“Generex or the “Company”), an innovative and integrated healthcare holding company with end-to-end solutions for patient centric care including the development of its innovative “Complete Vaccine”...
Feb 24, 2021 09:15 am ET
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Complete Vaccine™ Development Program
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has completed the mouse immunogenicity study with transgenic mice that have been genetically engineered...
Feb 03, 2021 09:00 am ET
Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call-in information and an updated agenda for the shareholder conference call on Friday February 5th at 9:00 am. During the call, Generex President &...
Jan 08, 2021 02:22 pm ET
Generex Biotechnology Announces Investor Conference Call Scheduled for Friday February 5, 2021 at 9:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday February 5, 2021 at 9:00 AM. Joseph Moscato, Generex President & Chief Executive Officer stated: “I am excited...
Dec 31, 2020 09:00 am ET
Generex and NuGenerex Immuno-Oncology Provide Update on Ii-Key COVID-19 Vaccine Development Program and Files Trademark Application for The Complete Vaccine™
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that its majority owned public entity, NuGenerex Immuno-Oncology, Inc. (NGIO), has filed for and expects to receive a...
Nov 23, 2020 08:30 am ET
Generex and NuGenerex Immuno-Oncology Ii-Key-SARS-CoV-2 Vaccine Partner Bintai Kinden Executes its Exclusive Distribution & Licensing Option for Australia and New Zealand
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) and subsidiary NuGenerex Immuno-Oncology today announced that their Ii-Key COVID-19 vaccine development partner Bintai Kinden Corporation...
Nov 19, 2020 08:30 am ET
Generex signs Worldwide Licensing Deal with China Partners on the Development of an Ii-Key-H1 Swine Influenza Vaccine
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a worldwide Licensing and Development Agreement with a consortium of partners in China...
Nov 18, 2020 08:30 am ET
Generex Inks $50 Million Licensing Deal with China Partners on the Cooperative Development of the Ii-Key Vaccine Platform
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has closed a $50 million Licensing and Development Agreement with a consortium of partners in...
Nov 12, 2020 09:00 am ET
Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine Program
Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, Executive Vice President of Research & Development at Generex and NuGenerex Immuno-Oncology will be featured on the Yo! Dr. Yo Show to provide an update on the...
Nov 04, 2020 09:15 am ET
Generex Announces the Signing of a Framework Agreement with The China CDC, Beijing Guoxin Haixiang Equity Investment Partnership and Beijing Youfeng International Consulting Co., Ltd on the Cooperativ
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has signed a Framework Agreement with the China CDC, Beijing Guoxin Haixiang Equity Investment...
Nov 03, 2020 12:00 pm ET
NuGenerex Immuno-Oncology Announces the Launch of a New Corporate Website
NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has launched its new corporate website to...
Oct 30, 2020 09:00 am ET
Generex Subsidiary NuGenerex Immuno-Oncology Announces Appointment of Dr. Tamera Coyne-Beasley to the Scientific Advisory Board for its COVID-19 Vaccine Development Program
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that Dr. Tamera-Coyne Beasley has joined the NGIO COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help...
Oct 13, 2020 09:24 am ET
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of a Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunotherapeutic Vaccine
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to announce that a review article on therapeutic cancer vaccines has been published in the peer-reviewed journal Cancers. The...
Oct 07, 2020 03:32 pm ET
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology on Thursday October 8, 2020 at 8:00 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for tomorrow’s investor conference call on Thursday October 8, 2020 at 8:00 AM Eastern time. The access information for the investor conference...
Oct 07, 2020 08:52 am ET
NuGenerex Immuno-Oncology Announces Closing of a Licensing & Distribution Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine
NuGenerex Immuno-Oncology (NGIO), a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce the closing of a Licensing & Distribution Agreement with Bintai...
Oct 06, 2020 08:30 am ET
Generex Subsidiary NuGenerex Immuno-Oncology Announces World Class Scientific Advisory Board Appointments for its COVID-19 Vaccine Development Program
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has formed the COVID-19 Vaccine Scientific & Clinical Advisory Board (SAB) to help guide the clinical...
Oct 02, 2020 12:48 pm ET
NuGenerex Immuno-Oncology Announces Shareholder Conference Call on Thursday October 8, 2020 at 8:00 AM
NuGenerex Immuno-Oncology (http://nugenerexio.com) is pleased to announce that the company will hold a shareholder conference call on Thursday October 8th at 8:00 AM. CEO Joseph Moscato will update its shareholders on its ongoing development...
Sep 25, 2020 09:00 am ET
Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) Services
Generex Biotechnology Corporation (OTCQB:GNBT) announces that its newly formed subsidiary NuGenHealth has signed a contract with Paradise Valley Family Medicine (PVFM) to provide connected care solutions for patient engagement, Remote Patient...
Sep 18, 2020 09:00 am ET
Generex Signs Binding Licensing & Research Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company and Bintai Kinden Corporation of Malaysia have signed an addendum binding the terms of the...
Sep 09, 2020 09:39 am ET
Generex Biotechnology Announces Analyst Report by Ari Zoldan at Seeking Alpha
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that an independent analyst report by Ari Zoldan was published on Seeking Alpha, a crowd-sourced content service for financial markets. Seeking Alpha publishes...
Aug 27, 2020 08:00 am ET
NuGenerex Immuno-Oncology Announces the Cancellation of Shareholder Conference Call Originally Scheduled for Today, Thursday, August 27, 2020
NuGenerex Immuno-Oncology (NGIO) today announced that it has cancelled the investor conference call originally scheduled to be held, Thursday, August 27, 2020 at 9:30 am. The conference call has been cancelled because the updates on the...
Aug 26, 2020 09:15 am ET
Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday, August 26th, 2020 at 9:30 AM Eastern
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company’s wholly owned subsidiary NuGenerex Health LLC has signed a joint venture agreement with Worldwide Digitech, LLC (WWDT) to form NuGenHealth LLC. Under...
Aug 25, 2020 03:10 pm ET
Generex Biotechnology Announces New Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced a new updated agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am. During the call, Generex President & CEO Joe Moscato will discuss the...
Aug 25, 2020 12:19 pm ET
Generex Biotechnology Announces Call-in Details and Updated Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the call in information and an updated agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am. During the call, Generex President & CEO Joe...
Aug 19, 2020 09:00 am ET
Generex Biotechnology Updates Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today updated the agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am. During the call, Generex President & CEO Joe Moscato will provide investors with an...
Aug 18, 2020 01:17 pm ET
Generex Signs a Memorandum of Understanding with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
This press release corrects a prior version published on August 18, 2020. The corrected press release reads: Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today has signed a non-binding memorandum of understanding (MOU) with...
Aug 18, 2020 09:00 am ET
Generex Announces Signed Agreement with Bintai Kinden to Advance the Clinical Development & Commercialization of Ii-Key-SARS-CoV-2 Coronavirus Vaccine for Malaysia
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that the company has signed a memorandum of understanding with Bintai Kinden Corporation of Malaysia for the development and commercialization of the Ii-Key-SARS-CoV-2...
Aug 17, 2020 09:00 am ET
Generex Biotechnology Announces Agenda for Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced the agenda for the shareholder conference call on Wednesday, August 26th at 9:30 am. During the call, Generex President & CEO Joe Moscato will provide investors with...
Aug 13, 2020 09:30 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen® for Vascular Repair
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to  announce that physicians at Yale University School of Medicine and the VA Connecticut Healthcare System have published a paper in the Journal of Vascular Surgery Cases...
Aug 04, 2020 09:00 am ET
NuGenerex Immuno-Oncology Announces Shareholder Conference Call on Thursday August 27th, 2020 at 9:30 AM to Provide Details on Impending Corporate Initiatives
NuGenerex Immuno-Oncology (NGIO) today announced that it will hold an investor conference call on Thursday, August 27th at 9:00 am. During the call, NGIO CEO Joe Moscato will discuss the company’s efforts to develop a vaccine for the COVID-19...
Aug 03, 2020 09:00 am ET
Generex Biotechnology Announces Shareholder Conference Call on Wednesday August 26th, 2020 at 9:30 AM to Provide Details on Impending Corporate Initiatives
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Wednesday, August 26th at 9:00 am. During the call, Generex President & CEO Joe Moscato will discuss the company’s...
Jul 27, 2020 09:15 am ET
Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the FDA has accepted their pre-IND briefing package for the Ii-Key-SARS-CoV-2 coronavirus prophylactic vaccine, and...
Jul 20, 2020 09:00 am ET
Generex Biotechnology Files Pre-IND Briefing Package with FDA for Ii-Key-SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has submitted a pre-IND briefing package to FDA requesting regulatory guidance on the Phase I/II clinical...
Jul 15, 2020 09:30 am ET
NuGenerex Immuno-Oncology Closes $50 Million Financing Facility
NuGenerex Immuno-Oncology (NuGenerex IO), today announced the closing of a $50 Million equity financing facility to support the company’s strategic and development plans. NuGenerex IO is now a public company, and once the S1 registration for this...
Jul 10, 2020 08:30 am ET
Generex Biotechnology Announces Corporate Update and Investor Conference Call: NuGenerex Immuno-Oncology Today Friday July 10, 2020 at 4:15 PM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for today’s investor conference call on Friday July 10th 2020 at 4:15 PM Eastern time. The access information for the investor conference call is as...
Jul 02, 2020 09:00 am ET
NuGenerex Immuno-Oncology Announces Plans to Address the New Emerging Pandemic Threat from G4 EA H1N1 Swine Influenza Virus Using Ii-Key-H1 Peptide Vaccine
NuGenerex Immuno-Oncology today announced that the company is launching a vaccine development effort to address the new, emerging pandemic threat from a newly identified swine influenza virus. On June 29, 2020 scientists in China published a paper...
Jul 01, 2020 09:00 am ET
NuGenerex Immuno-Oncology Announces Board of Directors
NuGenerex Immuno-Oncology is pleased to announce the Board of Directors who will help lead the company’s strategic plans to build a world-class immune-oncology organization. The Board is comprised of renowned leaders in the fields of oncology,...
Jun 26, 2020 09:00 am ET
NuGenerex Immuno-Oncology Announces Shareholder Conference Call July 10, 2020 at 4:15 PM
NuGenerex Immuno-Oncology is pleased to announce its inaugural shareholder meeting as a public stand-alone company. The company will introduce the management team and its world class board of directors and will update shareholders on our current...
May 22, 2020 09:45 am ET
Generex Subsidiary NGIO Advances COVID-19 Vaccine Program with the Manufacturing of Patent-Pending Ii-Key-SARS-CoV-2 Peptides
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that their COVID-19 vaccine program has reached a milestone with the manufacturing of 33 Ii-Key-SARS-CoV-2 peptides using...
May 04, 2020 08:30 am ET
Generex Biotechnology Initiates Peptide Manufacturing for Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has submitted a contract proposal to BARDA to develop a vaccine against the SARS-CoV-2 coronavirus using...
Apr 28, 2020 09:24 am ET
Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb Breast Cancer Trial
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to announce that the final results of the Phase IIb clinical trial  of AE37 +/- GM-CSF vaccine for the prevention of recurrence...
Apr 27, 2020 08:30 am ET
Generex Biotechnology Publishes Response to Congressional Letter Calling for COVID-19 Challenge Studies and Alternative Solution to Accelerate Vaccine Development
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today published a response to the April 20th letter from Congressional members to HHS Secretary Alex Azar and FDA Commissioner Stephan...
Apr 14, 2020 09:00 am ET
Generex Biotechnology Provides Update on the Development of an Ii-Key- SARS-CoV-2 Peptide Vaccine Against the COVID-19 Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company is working with corporate collaborators, academic advisors, and contract manufacturers, with guidance...
Apr 06, 2020 09:09 am ET
Generex Biotechnology CEO Offers an Open Letter to Shareholders and Provides an Update on Corporate Response to the COVID-19 Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) President & CEO Joseph Moscato offers an open letter to shareholders to provide an update on the company’s response, operationally and...
Mar 30, 2020 10:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutics’ Wound Conforming Matrix, Excellagen®, Awarded Strategic Acquisition Centers (SAC) Biologic Blanket Purchase Agreement (BPA) Contract
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) proudly announced that the company’s subsidiary Olaregen Therapeutics’ wound conforming matrix, Excellagen, has been awarded a Blanket...
Mar 30, 2020 08:30 am ET
Generex Participating on Expert Panel for Fierce Pharma & Fierce Healthcare Corona Virus Virtual Series
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) announced that today Dr. Eric von Hofe, PhD, Chief Scientific Officer of NuGenerex Immuno-Oncology  (NGIO), a Generex subsidiary, will be...
Mar 19, 2020 09:00 am ET
Generex Biotechnology Provides Guidance on the Safety of Ii-Key Peptide Vaccines for the Development of Effective Solutions to the SARS-CoV-2 Coronavirus Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on their work to develop a peptide vaccine against the new coronavirus SARS-CoV-2 using the company’s proprietary...
Mar 12, 2020 01:13 pm ET
Generex Subsidiary NuGenerex Immuno-Oncology (Formerly Antigen Express) Files Form 10 Registration Statement with the Securities and Exchange Commission
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company’s subsidiary NuGenerex Immuno-Oncology (NGIO) has filed the initial public filing of a Form 10...
Mar 11, 2020 02:40 pm ET
Generex Ii-Key Technology for Development of COVID-19 Vaccine Featured in Media
Generex Biotechnology Corporation (OTCQB:GNBT), and its subsidiary, NuGenerex Immune-Oncology (NGIO), have been featured in several news outlets and on a podcast regarding its Ii-Key vaccine platform and its development of a COVID-19 (coronavirus)...
Mar 10, 2020 10:07 am ET
Generex Biotechnology Subsidiary NuGenerex Immuno-Oncology Sponsors Susan G. Komen More Than Pink Walk
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that NuGenerex Immuno-Oncology is sponsoring the Susan G. Komen More than Pink Walk in Orlando, FL on Saturday March 14. The Orlando chapter of the Komen Foundation represents...
Mar 04, 2020 09:00 am ET
Generex Signs Contract with EpiVax to Develop Ii-Key Peptide Vaccines to Address the Coronavirus Pandemic
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract with EpiVax (https://epivax.com/) to use their computational tools to...
Mar 02, 2020 12:50 pm ET
Generex Signs Contract with Chinese Partners Beijing Zhonghua Investment Fund Management Co., LTD and Sinotek-Advocates International Industry Development (Shenzhen) Co., Ltd. to Develop a COVID-19 Va
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company has signed a contract from the Beijing Zhonghua Investment Fund Management Co., LTD. (an affiliate...
Mar 02, 2020 09:30 am ET
Generex Biotechnology Appoints Independent Director S. Gail Eckhardt, MD to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Dr. S. Gail Eckhardt, MD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Eckhardt...
Feb 27, 2020 11:20 am ET
Generex Provides Coronavirus Update: Generex Receives Contract from Chinese Partners to Develop a COVID-19 Vaccine Using Ii-Key Peptide Vaccines
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has received a contract from the China Technology Exchange, Beijing Zhonghua Investment Fund Management...
Feb 26, 2020 08:00 am ET
Generex Issues Clarification on Stock Dividends
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today clarified certain information regarding its stock dividends consisting of two shares of Generex stock for every five shares held, and two shares of NuGenerex...
Feb 24, 2020 09:21 am ET
Generex Congratulates their Shareholders as FINRA has Officially Posted the Approval of the Generex Corporate Action and Payment of the Generex and NuGenerex Immuno-Oncology Stock Dividends on Monday,
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that FINRA has officially posted the Generex 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology to the FINRA web site, and the dividends will be...
Feb 12, 2020 09:00 am ET
Generex Biotechnology Announces Investor Conference Dial-In Details Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines and Corporate Update Thursday February 13, 2020 at 11:00 AM EST
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced call-in details for the upcoming investor conference call on Thursday February 13th 2020 at 11:00am AM Eastern time. The access information for the investor...
Feb 10, 2020 09:00 am ET
Generex Biotechnology Announces Corporate Update and Investor Conference Call: Addressing the Coronavirus Pandemic with Ii-Key Peptide Vaccines - Thursday February 13, 2020 at 11:00 AM EST
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that Joe Moscato, President & Chief Executive Officer and the team from NuGenerex Immuno-Oncology will hold an investor conference call on Thursday February 13, 2020...
Feb 07, 2020 08:30 am ET
Generex Declares NEW Dividend RECORD DATE: Monday, February 17, 2020
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) is pleased to announce the successful completion of the FINRA review process for the dividend. After an exhaustive and long review, FINRA has determined that the original...
Feb 06, 2020 11:30 am ET
Generex Provides Stock Dividend Updates and Guidance
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced an update on the pending 2:5 stock dividends in Generex and NuGenerex Immuno-Oncology. Generex originally submitted the dividend request for a corporate...
Feb 06, 2020 09:30 am ET
Generex Biotechnology Discusses Coronavirus Solutions with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 6, 2020) - The Stock Day Podcast welcomed Generex Biotechnology (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Joseph Moscato and Dr. Eric Von Hofe joined Stock Day host Everett Jolly.
Feb 06, 2020 08:00 am ET
Generex Biotechnology Subsidiaries NuGenerex Immuno-Oncology and NuGenerex Diagnostics Working to Address the Coronavirus Pandemic and Emerging Risk of Avian Flu Using Ii-Key Peptide Vaccines
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company is working with third party groups and government agencies to reactivate the previously robust research...
Feb 05, 2020 09:00 am ET
Generex Biotechnology Appoints Independent Director Carol Nacy, PhD to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Dr. Carol Nacy, PhD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Nacy is a...
Feb 04, 2020 09:56 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Receives VAC Approval and Ships Excellagen® to the Arizona Indian Health Service
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has begun shipping Excellagen to the Indian Health Services in Arizona, following...
Jan 30, 2020 09:00 am ET
Generex Biotechnology Appoints Independent Directors Craig Eagle, MD and Thomas Leonard to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointments of Dr. Craig Eagle, MD and Mr. Thomas Leonard to the NuGenerex Immuno-Oncology (NGIO) Board of...
Jan 24, 2020 09:00 am ET
Generex Biotechnology Announces Interview with Richard Purcell, Executive Vice President of R&D
Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Richard Purcell, the company’s Executive Vice President of Research & Development conducted an interview with Mike Elliott of CEO Roadshow, which is available at:...
Jan 17, 2020 02:09 pm ET
Generex Biotechnology Provides Investor Conference Call Details Tuesday January 21, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced Call-in details for the upcoming investor conference call on Tuesday January 21, 2020 at 9:30 AM Eastern time. The access information for the investor conference call...
Jan 17, 2020 09:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Introduction of Excellagen Aesthetics™
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc., is introducing an exciting new product, Excellagen Aesthetics™ for the...
Jan 16, 2020 12:28 pm ET
Generex Biotechnology Provides 2019 Year-End Summary & 2020 Plans
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to provide the investment community with a review of the many challenges overcome and accomplishments achieved in 2019, with a...
Jan 15, 2020 03:16 pm ET
Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday January 21, 2020 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Tuesday January 21, 2020 at 9:30 am. Topics that will be covered in the call; The illegal selling of 8.4 million...
Jan 13, 2020 12:28 pm ET
Generex Biotechnology Announces Interview with President & CEO Joe Moscato
Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Joe Moscato, the company’s President & Chief Executive Officer conducted an interview with Mike Elliott of CEO Roadshow, which is available at:...
Jan 10, 2020 08:00 am ET
Generex Biotechnology Announces Update to Shareholder Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that the pay day for the two previously announced dividends in Generex Biotechnology and in NuGenerex Immuno-Oncology have been postponed due to  FINRA’s...
Jan 08, 2020 09:43 am ET
Generex Biotechnology to be Featured at 2020 Wall Street Conference
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has been selected as the featured organization to present at the 2020 Wall Street Conference and Retreat to be held in West Palm Beach, FL from February 19 to...
Jan 03, 2020 08:00 am ET
Generex Biotechnology Announces Update to Shareholder Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that the pay day for the two previously announced dividends in Generex Biotechnology and in NuGenerex Immuno-Oncology have been delayed due to the ongoing...
Dec 18, 2019 11:21 am ET
Generex Biotechnology Issues Shareholder Alert
Generex Biotechnology Corporation (OTCQB: GNBT) has issued a shareholder alert regarding recent trading activity that has adversely affected the company and its shareholders. As a standard practice, Generex monitors the trading in its securities,...
Dec 11, 2019 09:00 am ET
Generex Biotechnology Appoints Independent Director Marvin S. Hausman, MD to the NuGenerex Immuno-Oncology Board of Directors
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Dr. Marvin S. Hausman, MD to the NuGenerex Immuno-Oncology (NGIO) Board of Directors. Dr. Hausman...
Dec 10, 2019 09:30 am ET
Generex Biotechnology Announces New Structure, Pay Date and Ex-Date for the Previously Postponed Shareholder Stock Dividend and Declares a New Share Dividend in NuGenerex Immuno-Oncology
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced revisions to the previously announced share dividend. Generex will now pay the postponed 1:1 dividend at a ratio of 2 to 5; i.e. for every 5 shares of...
Dec 09, 2019 10:47 am ET
Generex Biotechnology Provides Update on Pending Dividend
Generex Biotechnology Corporation (OTCQB: GNBT) today provided guidance on the postponed stock dividend. Tomorrow, Tuesday December 10, 2019 at 9:30 AM, Generex will announce the new pay date and ex-date for the dividend and will announce a new...
Dec 05, 2019 10:29 am ET
Generex Biotechnology Announces Funding Update
Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that the company has finalized agreements to provide significant funding for ongoing operations, launching new businesses, and advancing the commercial development of new...
Nov 27, 2019 04:05 pm ET
Generex Biotechnology Announces Postponement of Pending 1:1 Dividend
Generex Biotechnology Corporation (OTCQB: GNBT) today announced that due to the issues announced yesterday in a shareholder alert, and because of the resulting sharp decline of over 150% in our share price, the Company has decided to postpone the...
Nov 27, 2019 11:10 am ET
Reminder: Generex Investor Conference Call Friday, November 29, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer...
Nov 26, 2019 01:39 pm ET
Generex Biotechnology Issues Shareholder Alert
Generex Biotechnology Corporation (OTCQB: GNBT) has issued a shareholder alert regarding recent trading activity that has adversely affected the company and its shareholders. It has been brought to our intention that Creek Mountain Fund, from which...
Nov 25, 2019 08:30 am ET
Generex Biotechnology Signs Stock Purchase Agreement to Acquire 51% of ALTuCELL, Inc.
Generex Biotechnology Corporation (OTCQB: GNBT) is excited to announce that the Company has signed a Stock Purchase Agreement to acquire a 51% controlling interest in ALTuCELL, a privately held biotechnology company, in a stock and cash...
Nov 13, 2019 02:03 pm ET
Generex Biotechnology Announces Investor Conference Call Scheduled for Friday November 29, 2019 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Friday November 29, 2019 at 9:30 am. Joseph Moscato, Generex President & Chief Executive Officer stated: “I look...
Nov 08, 2019 09:48 am ET
Generex Biotechnology Provides Guidance: Form 10k Annual Report will be filed Tuesday Morning November 12th 2019
Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that its 10k annual report will be filed Tuesday morning within the time afforded to public companies under the standard filing extension. Generex has received many calls in...
Nov 05, 2019 09:15 am ET
Generex Biotechnology Announces First-in-Human Clinical Trial of the ALTuCELL Cellular Therapy Product Altsulin® (Microencapsulated Sertoli Cells)
/PRNewswire/ -- Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that the Company’s soon to be subsidiary ALTuCELL, in collaboration with Dr. Jaime Guevara-Aguirre, has submitted the proof-of-concept Phase IIa clinical trial...
Oct 29, 2019 08:30 am ET
Generex Biotechnology Announces Extension to the Pay Date for the Previously Declared 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that the company will file for an extension to file its 10K for the fiscal year ended July 31, 2019 with the SEC, and therefore the pay date for the 1:1...
Oct 28, 2019 09:56 am ET
Reminder: Generex Investor Conference Call Tomorrow October 29, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer...
Oct 25, 2019 02:06 pm ET
Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday October 29, 2019 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Tuesday October 29, 2019 at 9:30 am. Joseph Moscato, Generex President & Chief Executive Officer stated: “I look...
Oct 25, 2019 11:00 am ET
Generex Announces Results of Annual Stockholders’ Meeting
/(Business Wire)/-- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the results of the annual meeting of the Company’s stockholders held on October 25, 2019. Brian McGee,...
Oct 18, 2019 09:15 am ET
Generex Biotechnology Chief Medical & Scientific Officer Dr. Jason Terrell, MD is Awarded the 2019 Shepperd Pathfinder Award from the John Ben Shepperd Public Leadership Institute
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased and proud to announce that the company’s Chief Medical and Scientific Officer Dr. Jason Terrell, MD was recently awarded the Shepperd Pathfinder Award for his work in cancer research. In...
Oct 15, 2019 09:00 am ET
Generex Biotechnology Announces Merger with Public Vehicle for Public Trading of NuGenerex Immuno-Oncology
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced a merger transaction with a public company that is DTC eligible and current with its SEC filings to serve as a vehicle for the quotation of the common stock of its...
Oct 14, 2019 09:30 am ET
Reminder: Generex Investor Conference Call Tomorrow October 15, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer...
Oct 10, 2019 09:15 am ET
Generex Biotechnology Announces that Excellagen® Inventor, Dr. Lois Chandler will Present Clinical Data on Rapid Healing of Diabetic Foot Ulcers at The Symposium on Advanced Wound Care (SAWC) Fall Mee
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased and proud to announce that Dr. Lois Chandler, inventor of Excellagen and an advisor to our subsidiary, Olaregen Therapeutix, will be presenting the poster entitled “Wound Conforming Matrix...
Oct 07, 2019 08:30 am ET
Generex Biotechnology Corporation Discusses Upcoming Revenue Increases and Growth with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - October 7, 2019) - The Stock Day Podcast welcomed Generex Biotechnology Corporation (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. CEO of the Company, Joseph Moscato, joined Stock Day host Everett Jolly.
Oct 01, 2019 12:40 pm ET
Generex Biotechnology Announces Investor Conference Call Scheduled for Tuesday October 15, 2019 at 9:30 AM
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Tuesday October 15, 2019 at 9:30 am. Joseph Moscato, Generex President & Chief Executive Officer stated: “I look...
Oct 01, 2019 09:15 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Launches Excellagen Wound Conforming Matrix 3.0 cc Pre-Filled Syringe
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is pleased to announce that their subsidiary, Olaregen Therapeutix, Inc. today officially launched the Excellagen 3.0 cc pre-filled syringe,...
Sep 30, 2019 09:49 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Signs National Sales & Distribution Agreement With AvKare Medical to Distribute Excellagen® Throughout the VA Hospital System
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company, has entered into a national sales and distribution agreement with AvKare Inc. to...
Sep 27, 2019 09:00 am ET
Generex Biotechnology Announces Plans to Establish the NuGenerex Diabetes Research Center in Collaboration With Arizona Endocrinology Group & Paradise Valley Medical Family Medicine
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce plans to establish the NuGenerex Diabetes Research Center in collaboration with Arizona Endocrinology Group and Paradise Valley Family Medicine, P.C., our partners in our...
Sep 20, 2019 11:03 am ET
Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/ GNBT/quote) today announced that the legal and regulatory process to retire the 20,375,900 “Pool” shares is complete. The Pool shares have been...
Sep 17, 2019 09:00 am ET
Generex Biotechnology Announces First Patient Enrolled in the Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (KeytrudaÒ) for the Treatment of Triple Negative Breast Cancer
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the NSABP Foundation, Inc. (NSABP) has enrolled the first patient in the study: A Phase II Clinical Trial of...
Sep 16, 2019 02:51 pm ET
Generex Announces That the Process to Retire 20,375,900 GNBT “Pool Shares” is Complete
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the legal and regulatory process to retire the 20,375,900 “Pool” shares is complete. Joe Moscato, Generex President &...
Sep 12, 2019 12:20 pm ET
Generex Biotechnology Announces Webcast and Invites All Shareholders to See and Listen to the Corporate Presentation from the 21st Annual H.C. Wainwright Global Healthcare Investment Conference
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the presentation delivered by Joe Moscato, President & Chief Executive Officer and Richard Purcell, Senior Vice President of Research to the H.C. Wainwright Global...
Sep 10, 2019 08:30 am ET
Generex Biotechnology Signs Letters of Intent to Establish NuGenerex Health MSO with Arizona Endocrinology Center & Paradise Valley Family Medicine
Generex Biotechnology Corporation (OTCQB:GNBT) announces that the Company has signed letters of intent with Arizona Endocrinology Center and Paradise Valley Family Medicine to establish NuGenerex Health, LLC, a management services organization...
Sep 09, 2019 09:00 am ET
Generex Biotechnology Signs Letter of Intent to Acquire 51% in ALTuCELL, Inc. and their Cellular Therapy Product Altsulin® with Patented Microencapsulation Technology for the Treatment of Type I Diabe
Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that the Company has signed a binding letter of intent (LOI) to partner with ALTuCELL, a privately held biotechnology company in a stock and cash transaction. ALTuCELL, Inc. is...
Sep 06, 2019 12:19 pm ET
Generex Announces Date for Annual Shareholder Meeting and Pending Retirement of 20,375,900 GNBT “Pool Shares”
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the annual shareholder meeting is set for October 25, 2019. Shareholders of record as of September 3, 2019 are...
Sep 05, 2019 10:21 am ET
Generex Announces Webcast
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the presentation to be delivered by Joe Moscato, President & Chief Executive Officer at the H.C. Wainwright Global Investor Conference will be available starting Monday...
Sep 03, 2019 01:50 pm ET
Generex Biotechnology Confirms Record Date for 1:1 Dividend
Generex Biotechnology Corporation (OTCQB:GNBT) today confirmed that the record date for the 1:1 (100%) stock dividend was recorded on August 30, 2019, and the dividend will be paid on October 29th  to all shareholders who hold their shares through...
Aug 26, 2019 11:09 am ET
Generex Biotechnology Announces Time Slot for CEO Joe Moscato to Present at H.C. Wainwright Healthcare Conference
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, President & Chief Executive Officer, will deliver a presentation on Monday, September 9, 2019 at 3:25 PM at the H.C. Wainwright Global Investor Conference. Mr....
Aug 23, 2019 03:05 pm ET
Generex Biotechnology Reiterates 1:1 Stock Dividend for Clarity in the Market and Provides Details on Capital Structure
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call...
Aug 19, 2019 09:00 am ET
Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) is pleased to announce that Generex has acquired an additional 38% of Olaregen Therapeutix for a total Generex ownership of approximately 99% after the share exchange at...
Aug 16, 2019 10:42 am ET
Generex Biotechnology Announces Plans for NuGenerex Immuno-Oncology Spinout through a Targeted Acquisition of a Public Company and Planned Merger with Kiromic
Generex Biotechnology (www.generex.com) (OTCQB:GNBT) today announced that the Company has identified a public, development stage company that is fully reporting and current on its filings with the SEC, and DTC eligible that will serve as a vehicle...
Aug 15, 2019 12:51 pm ET
Generex Biotechnology Defines 1:1 Stock Dividend and Provides Details on Capital Structure
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today provided additional guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Due to high call...
Aug 12, 2019 08:00 am ET
Generex Biotechnology Announces Update to the Previously Declared 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today announced that it was proceeding with the dividend in anticipation of listing on Nasdaq. Therefore, Generex plans to reward Generex’s loyal shareholders by...
Aug 09, 2019 12:27 pm ET
Generex News Alert: Generex to Announce Positive Shareholder News on Monday August 12, 2019 at 8 AM Payment Details for the 1:1 GNBT Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (“Generex”) today provided a news alert for GNBT shareholders that the Company will make an announcement on Monday August 12, 2019 at 8 AM pertaining to the payment of the previously...
Aug 08, 2019 09:00 am ET
Generex Biotechnology Announces Interview with President & CEO Joe Moscato
Generex Biotechnology Corporation (OTCQB:GNBT) today announced that Joe Moscato, the company’s President & Chief Executive Officer conducted an interview with the Wall Street Analyzer, which is available at:...
Aug 01, 2019 09:15 am ET
Generex Biotechnology Welcomes MediSource Partners to the NuGenerex Family of Companies
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to welcome MediSource Partners (https://medisourcepartners.com) to the NuGenerex family of subsidiary companies. MediSource is a national distributor of medical devices,...
Jul 31, 2019 09:15 am ET
Generex Biotechnology Introduces Pantheon Medical, the Newest Member of the NuGenerex Family of Companies
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is proud to introduce Pantheon Medical (https://pantheonortho.com) as the newest member of the NuGenerex family of subsidiary companies. Pantheon is a manufacturer of orthopedic foot...
Jul 29, 2019 09:25 am ET
Generex Biotechnology Provides Guidance on 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today provided guidance for investors on the company’s plans for the GNBT up-list to Nasdaq and the payment of the 1:1 share dividend to shareholders. Joseph Moscato, Generex...
Jul 26, 2019 09:00 am ET
Generex Biotechnology Provides a Summary of Its Investor Conference Call Held on July 25, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today provided a summary of the investor conference call held yesterday, July 25, 2019 at 4:00 pm during which Joseph Moscato, Generex President & Chief Executive Officer updated...
Jul 25, 2019 09:00 am ET
Reminder: Investor Conference Call Today July 25, 2019 Management to Provide Details on Generex Up-list and 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer...
Jul 19, 2019 09:15 am ET
Generex Biotechnology Announces Satisfaction of Debt Obligation
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it has repaid a long-standing $3,150,972 debt with newly issued restricted common voting shares of Generex (GNBT) in full satisfaction and accord of all debts and...
Jul 16, 2019 11:59 am ET
Generex Biotechnology Announces Investor Conference Call Scheduled for July 25, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Thursday July 25, 2019 at 4:00 pm to update investors on the company’s plans for the GNBT up-list and the previously...
Jul 15, 2019 09:15 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors APMA Annual Scientific Meeting
/PRNewswire/--Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company’s subsidiary Olaregen Therapeutix, an emerging regenerative medicine company was a Silver Sponsor of the American Podiatric Medicine Association...
Jul 12, 2019 09:00 am ET
Generex Biotechnology Announces Closing on Acquisition of MediSource Partners
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce the Company has completed the acquisition agreement to acquire assets and operations of Medisource Partners, an FDA-registered distributor of medical and surgical products...
Jul 11, 2019 09:00 am ET
Generex Biotechnology Announces Acquisition of Pantheon Medical Foot & Ankle
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal,...
Jul 10, 2019 09:15 am ET
Generex Biotechnology Provides Fiscal Year Overview
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided an overview of Generex’s accomplishments for the fiscal year ending on July 31, 2019, as outlined herein....
Jul 02, 2019 09:15 am ET
Generex Engages Donohoe Advisory to Assist with Uplisting
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that Generex has engaged Donohoe Advisory Associates LLC (“Donohoe Advisory”) in connection with its efforts to...
Jul 01, 2019 08:30 am ET
The Stock Day Podcast Hosts Generex Biotechnology Corporation to Discuss Uplisting on the NASDAQ
Phoenix, Arizona--(Newsfile Corp. - July 1, 2019) - The Stock Day Podcast welcomed Generex Biotechnology Corporation (OTCQB: GNBT) ("the Company"), an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. CEO and President, Joseph Moscato, joined Stock Day host Everett Jolly.
Jun 28, 2019 09:15 am ET
Generex Announces Update on 1:1 Dividend and NASDAQ Listing
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today provided guidance on the previously announced 1:1 GNBT stock dividend.  After discussing our listing with Nasdaq officials and our...
Jun 26, 2019 09:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Receives American Podiatry Medical Associations “Seal of Approval” for Excellagen Wound Conforming Matrix
Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), announced today that their subsidiary, Olaregen Therapeutix, Inc., received the prestigious “Seal of Approval” from the American Podiatric...
Jun 25, 2019 09:00 am ET
Generex Signs Letter of Intent with Kiromic to Merge with NuGenerex Immuno-Oncology Forming a Multi-Platform Clinical Stage Immunotherapy Company
Generex Biotechnology Corporation (“Generex”) (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that Generex has signed a Letter of Intent (“LOI”) with Kiromic, Inc., a clinical stage immunotherapy company...
Jun 24, 2019 08:30 am ET
Generex Investor Conference Call Recording Now Available Online Detailing 1:1 Stock Dividend, Merger for NuGenerex Immuno-Oncology and Go Forward Plans
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the audio recording of its investor conference call, is now available for listening on our website www.generex.com, and...
Jun 21, 2019 08:30 am ET
Generex Announces That the Pool Shares for the Benefit of Generex Will Be Retired and Put Back into the Corporate Treasury Following Payment of the 1:1 Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the “Pool” shares controlled for the benefit of Generex by Joe Moscato, President and Chief Executive Officer of...
Jun 20, 2019 09:00 am ET
Generex Declares 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company today declared the previously announced 1:1 common stock dividend.  The Record Date for the...
Jun 17, 2019 09:00 am ET
Reminder: Investor Conference Call Friday June 21st, 2019
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief Executive Officer...
Jun 07, 2019 09:30 am ET
Generex Provides Update to Pending 1:1 Stock Dividend
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), in response to the large volume of investor calls, today provided an update on its new 1:1 dividend that has been approved by the Generex...
Jun 04, 2019 09:00 am ET
Generex Biotechnology CEO Joe Moscato To Present at H.C. Wainwright Healthcare Conference
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, the company’s Chief Executive Officer and his team of seasoned industry leaders are scheduled to present at the H.C. Wainwright Global Investor Conference to be...
Jun 03, 2019 09:00 am ET
Generex Biotechnology Announces Date for Rescheduled May 15th Investor Conference Call to Present Organizational Roadmap & Update on Investor Dividend, Product Launch, New Acquisitions, Financing, Exp
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has rescheduled the investor conference call originally scheduled for May 15, 2019. The new date for the...
May 31, 2019 09:45 am ET
Generex Biotechnology Announces Share Dividend & Strategic Plans
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company plans to declare a 1:1 stock dividend, contingent upon the successful up listing to NASDAQ, to...
May 16, 2019 09:00 am ET
Generex Biotechnology Announces that its Subsidiary Olaregen Therapeutix Launches Excellagen at The Symposium on Advanced Wound Care (SAWC) in San Antonio, TX
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that its Subsidiary, Olaregen Therapeutix has officially launched Excellagen Wound Conforming Matrix. Generex and...
May 15, 2019 09:00 am ET
Generex Biotechnology Announces Postponement of Its May 15th Investor Conference Call
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that the company has postponed the investor conference call scheduled for May 15, 2019.  Joseph Moscato, President & Chief...
May 02, 2019 09:15 am ET
Generex Biotechnology Subsidiary NuGenerex Diagnostics Announces Sales for its Rapid Point-of-Care Malaria Diagnostic Test Kit
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that their wholly-owned subsidiary NuGenerex Diagnostics LLC, (www.nugenerexdiangostics.com) has filled an...
Apr 18, 2019 01:08 pm ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Sponsors Prestigious Diabetic Limb Salvage Conference in Washington D.C.
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Olaregen Therapeutix participated as a sponsor of the prestigious...
Apr 09, 2019 03:25 pm ET
Kali-Extracts To Present Cannabis Treatment R&D For $170 Million In Pharmaceutical Market Opportunity On April 17th
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online presentation scheduled next week for Wednesday, April 17th, where management will provide details on its patented cannabis...
Apr 08, 2019 09:00 am ET
Generex Biotechnology Corporation Appoints Mark J. Prioletti to the Board of Directors
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of Mark J. Prioletti to the Board of Directors. He is a highly experienced...
Apr 04, 2019 03:35 pm ET
Generex Addresses Shareholder Concern Over 8-K and Quarterly Filing
via NEWMEDIAWIRE -- Generex would like to clarify the discussions surrounding the filed 10-Q ending the period of January 31, 2019, or the second quarter, filed on March 25, 2019, and its subsequent non-reliance 8-K filed on March 28, 2019. The...
Mar 29, 2019 09:00 am ET
Upmarket Deal at $2.50 Per Share Saves Generex Biotechnology Shareholders $14+ Million
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce that the company has successfully renegotiated a mutually agreed upon purchase price for certain...
Mar 26, 2019 09:00 am ET
Generex Biotechnology Partner Olaregen Therapeutix, Inc. Selected to Present a Formal Poster Session at Prestigious Diabetic Limb Salvage Meeting
via NEWMEDIAWIRE – Generex Biotechnology Corporation (OTCMKTS: GNBT) today announced that its subsidiary, Olaregen Therapeutix, Inc., has been selected to present clinical data and a subset analysis of the Excellagen clinical trial dataset in a...
Mar 22, 2019 12:09 pm ET
USMJ and PURA Update Dividend Distribution Plans With PJET and NOUV To Include New Developments With WCVC and KALY
via OTC PR WIRE -- North American Cannabis Holdings, Inc. (USOTC: USMJ) (“USMJ”) and Puration Inc. (USOTC: PURA) (“PURA”) today published an update on the progress the two companies are making toward their respective planned dividend...
Mar 20, 2019 01:45 pm ET
KALY Phase One Cannabis Extract COPD Research To Be Published This Friday, March 22, 2019
via OTC PR WIRE --   Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company plans to publish its phase one research on the pilot treatment of Chronic Obstructive Pulmonary Disease (COPD) in...
Mar 18, 2019 01:08 pm ET
KALY Initiates Phase Two Cannabis Extract COPD Treatment Study
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced Professor Jeffry Osbourn, Ph.D., from the University of Kentucky and the principal of Biomedical Science Research Group (BSRG), and...
Mar 12, 2019 09:00 am ET
Generex Biotechnology Announces the Appointment of Chief Commercial Officer
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), is proud to announce the appointment of Lance Goudzwaard as the Chief Commercial Officer for NuGenerex Distribution...
Mar 08, 2019 12:53 pm ET
KALY Cannabis Patent Featured In PURA Report On Progress Toward $5 Million Sales Goal
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced the company’s recent advances developing a CBD extract for infusion into a beverage at a 25 mg concentration were featured in a...
Mar 08, 2019 09:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Announces the Appointment of Vice President of Business Strategy
via NEWMEDIAWIRE -- Olaregen Therapeutix, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of John P. Sentman as Vice President of...
Mar 07, 2019 10:47 am ET
Puration Signs New CBD Beverage Distribution Orders With Even Bigger Orders Underway Fueling M&A Interest
via OTC PR WIRE -- Puration, Inc. (USOTC: PURA) today published a presentation, to review new orders, opportunities and partnerships stemming from the EVERx CBD Sports Water event this past weekend at the Arnold Sports Festival. EVERx CBD Sports...
Mar 01, 2019 09:00 am ET
Generex Investor Conference Call Now Available Online
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the information for its investor conference call, is now available to listen and read on our...
Feb 26, 2019 12:22 pm ET
PURA - Puration Announces Analyst Update Report Coming Thursday February 28, 2019
via OTC PR WIRE --  Puration, Inc. (USOTC: PURA) today announced an upcoming analyst update report expected to be published this Thursday, February 28, 2019.  The report expected on Thursday will be a second update from Goldman Small Cap Research...
Feb 26, 2019 08:00 am ET
Reminder: Investor Conference Call Today, February 26, 2019; Management to Provide Update on Initiatives & Strategic Plans, Call-in Details
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced the following access information for its investor conference call, to be hosted by President & Chief...
Feb 21, 2019 11:15 am ET
KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary...
Feb 19, 2019 09:00 am ET
Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company’s subsidiary Regentys Corporation, a clinical stage regenerative medicine...
Feb 15, 2019 09:00 am ET
Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), today announced an agenda for the investor conference call to be presented Tuesday, February 26, at 11:00 AM....
Feb 12, 2019 09:40 am ET
Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (OTCQB: GNBT) is pleased to announce that Marshal Schictman, Esq. has joined the executive management team as Executive Vice President, General Counsel to oversee the company’s M&A activities,...
Feb 05, 2019 02:18 pm ET
KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today published a preview of the recently announced long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in...
Feb 04, 2019 01:53 pm ET
Generex Biotechnology Responds to Demand for Payment
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) provided a response to the demand for payment from Alpha Capital Anstalt. As reported in our 8-K filed on January 31,...
Feb 01, 2019 08:54 am ET
KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview
DALLAS, Feb. 1, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced a preview presentation scheduled for next week, on Tuesday, February 5th, to be published on line by KALY CEO Fred Ferri with Professor Jeffry Osbourn, Ph.D., from the University of Kentucky.  In addition to the previously disclosed in vitro genomics study to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on Chronic Obstructive Pulmonary Disease (COPD) patients, KALY has also competed a long-term, pilot stu
Jan 30, 2019 01:25 pm ET
KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today released a corporate update that includes the latest on KALY’s developments with Puration, Inc, (USOTC: PURA) (“PURA”) and Generex...
Jan 29, 2019 09:00 am ET
Generex Biotechnology Announces Investor Conference Call Scheduled for February 26, 2019
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT), today announced that it will hold a conference call on Tuesday, February 26th at 11:00 am to update investors on the completed share dividend for NuGenerex...
Jan 25, 2019 10:35 am ET
KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled for Wednesday next week on January 30, 2019.  The presentation will include updates on KALY’s...
Jan 25, 2019 09:00 am ET
Generex Launches DME-IQ, the “Smart Solution” for In-Office Management of Durable Medical Equipment
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) announced today that its wholly-owned subsidiary NuGenerex Distribution Solutions 2, LLC (NDS) has launched DME-IQ, a...
Jan 24, 2019 09:00 am ET
Generex Subsidiary NuGenerex Diagnostics Announces CE-Mark Certification for its Rapid Point-of-Care Express II Syphilis Treponemal Assay
via NEWMEDIAWIRE -- NuGenerex Diagnostics LLC, (www.nugenerexdiagnostics.com) a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT), announced today receipt of the CE Marking Certification for its rapid...
Jan 23, 2019 09:00 am ET
Generex Announces REVISED Record Date for NuGenerex Immuno-Oncology Stock Dividend
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has REVISED the record date for the previously announced dividend to Generex shareholders of...
Jan 22, 2019 10:00 am ET
Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to provide the investment community with a review of the many accomplishments achieved in 2018, with a vision...
Jan 17, 2019 08:34 am ET
Kali-Extracts and Puration Announce First Ever 25 mg CBD Extract Formulation For Beverage Infusion
via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) and Puration, Inc, (USOTC: PURA) (“PURA”) today announced a new 25 mg CBD Extract formulation for beverage infusion.  KALY owns and manages a...
Jan 16, 2019 02:10 pm ET
Generex Announces Record & Payment Dates for NuGenerex Immuno-Oncology Stock Dividend
via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company will dividend Generex shareholders with shares in our wholly-owned subsidiary...
Jan 16, 2019 09:00 am ET
Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http:/
Jan 14, 2019 09:00 am ET
Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives & Strategic Plans
via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (OTCQB: GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), today announced the following access information for its investor conference call, to be hosted by President & Chief...
Jan 11, 2019 09:00 am ET
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen® Wound Conforming Gel Matrix with Three Dosage Options
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Olaregen Therapeutix Inc., a subsidiary of Generex Biotechnology will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue Based Product or CTP for wound healing. The 0.5 cc and a 0.8 cc syringes will be utilized to treat smaller wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure ulcers, and in patients who have undergone MOHs surgery for removal of cancerous tissue. The
Jan 10, 2019 09:15 am ET
Generex Biotechnology Announces Acquisition of Surgical Supply and Distribution Company
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. Under the terms of the deal, Generex will acquire all of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, on a debt free basis, for One Million Dollars ($1,000,000) worth
Jan 10, 2019 08:00 am ET
Generex Biotechnology Announces Investor Conference Call; Management to Provide Update on Acquisitions, Financing Initiatives & Strategic Plans
Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) today announced that it will hold an investor conference call on Wednesday, January 16th, at 4:00 p.m. to update investors on the previously announced and pending acquisitions that offer significant value to the Generex parent company. Joseph Moscato, Generex President &
Jan 09, 2019 09:00 am ET
Generex Biotechnology Announces Acquisition of Surgical Device Manufacturer
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, and an FDA letter related to balanced plating system, on a debt free basis, for One Million Four Hundred Thousand Dollars ($1,400,000) worth of Ge
Jan 08, 2019 01:29 pm ET
Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.
via OTC PR WIRE -- Generex Biotechnology Corporation (GNBT) is pleased to announce that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc., a New York based regenerative medicine company that is preparing to launch its...
Jan 08, 2019 09:15 am ET
Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc., a New York based regenerative medicine company that is preparing to launch its proprietary, patented, wound conforming gel matrix, Excellagen® an FDA 510K Cleared wound healing product cleared for the treatment of 17 types of wounds including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds,
Jan 08, 2019 08:00 am ET
Generex Biotechnology Announces the Launch of a New Corporate Website
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has relaunched its corporate website to provide details on a revamped organizational structure, a talented and experienced management team, and a forward-looking vision for Generex as an integrated life science holdings company. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to opti
Jan 07, 2019 03:42 pm ET
Generex Biotechnology Introduces Treatment Alternative to $6 Billion Ulcerative Colitis Surgery Market
via OTC PR WIRE  -- Generex Biotechnology Corporation (OTC:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Regentys™ Corporation, a regenerative medicine company focused on developing novel treatments for...
Jan 07, 2019 11:55 am ET
KALY - Kali-Extracts Analyst Research Report Featuring New Cannabis Biotechnology Business Set For Release Tomorrow
via OTC PR WIRE --  Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) (“KALY”) today confirmed the previously announced analyst research report featuring the company’s new cannabis biotechnology business will be released tomorrow.  On November 15th,...
Jan 07, 2019 09:15 am ET
Generex Biotechnology Completes Acquisition of Regentys Corporation
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has completed the acquisition of 51% of Regentys™ Corporation, a regenerative medicine company focused on developing novel treatments for patients with gastrointestinal (GI) disorders. The terms of the deal include the previously reported upfront payment of $400,000, plus $14.6 million to be paid according to a milestone-based schedule. Details of the transaction can be found in the Generex 8K filing with the SEC.
Jan 07, 2019 08:00 am ET
Generex Biotechnology CEO Joe Moscato Attending J.P. Morgan Healthcare Conference
Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that Joe Moscato, the company’s CEO is attending the annual J.P. Morgan Healthcare Conference from January 7 to 9, 2019. Mr. Moscato is meeting with leading healthcare investors to present the corporate vision for Generex Biotechnology as an integrated healthcare holding company with a unique strategy to provide end-to-end, patient centric solutions to enhance the doctor patient relationship.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.